Find your next paid study

UNC Lineberger Comprehensive Cancer CenterNCT05578326

Non Small Cell Lung Cancer

Phase Ib/II Study of Safety and Efficacy of EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for p…

VA Office of Research and DevelopmentNCT05467748

~$10 – $5,625

Phase 2

A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell L…

B-Cell LymphomaB Acute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+6 more

Acute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)Chronic Myelogenous Leukemia+15 more

~$10 – $7,500

John ListerNCT05281809

Observational

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematologi…

Masonic Cancer Center, University of MinnesotaNCT01962636

Observational

Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers

This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lun…

Esophageal CarcinomaLung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8+14 more

M.D. Anderson Cancer Center

Extensive Stage-small Cell Lung Cancer

A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab …

Daiichi SankyoNCT06362252

~$10 – $7,500

Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants

The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observa…

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+1 more

NICHD Neonatal Research NetworkNCT00063063

~$10 – $1,125

Phase 2

ASsessment Of RiLuzole To Reduce Paroxysmal Episodes of Atrial FIbrillatiON (The SOLUTION Study)

Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhy…

Atrial Fibrillation Paroxysmal

University of UtahNCT05292209

Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally …

A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced can…

Hepatocellular CarcinomaSquamous Cell Non-Small Cell Lung CancerGerm Cell Tumor

Zymeworks BC Inc.NCT07164313

~$10 – $8,750

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Plasma Cell Disorders

~$10 – $750

Mayo ClinicNCT06252948

Melanoma (Skin)Non Small Cell Lung CancerBreast Cancer

A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501…